Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on its lead program QLS-215, which is in preclinical development for the treatment of hereditary angioedema, at the following upcoming virtual investor conferences:
- Oppenheimer Rare and Orphan Disease Summit. Presentations will be available on-demand on May 21, 2021.
- Jefferies Virtual Healthcare Conference on June 3, 2021 at 9:30am ET.
Webcasts of the events can be accessed from the investors section of www.catabasis.com . Archived replays will be available for 30 days following the event.
About Catabasis
At Catabasis Pharmaceuticals, our mission is to bring hope with life-changing therapies to patients and families. Our lead program, QLS-215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210514005065/en/
Catabasis Contacts:
Investor relations:
Andrea Matthews
investors@catabasis.com
Media:
Elizabeth Higgins
media@catabasis.com